

Date and Time: 14th & 15th October 2013, 1000 - 1600

Minutes: Final

**Guideline Development Group Meeting
9 & 10**

Place: *National Clinical Guideline Centre (day 1) and Royal Institute of
British Architects (day 2)*

Present: Stephanie Amiel (Chair)
Arthur Durrant
Michael Flynn
Roger Gadsby (present for day 1)
Peter Hammond
Mike Kendall
Vib Mistry (day 2, morning only)
Henrietta Mulnier
Vicky Ruzsala (day 1)
Stuart Smellie
Perdy van den Berg (day 2)
Liz Avital (day 2, afternoon only)
Bernard Higgins (day 1, day 2 morning only)
Gus Brooks
Angela Cooper (day 2)
Emily Davies
Chris Kiff (day 1)
Nancy Pursey (notes)
Dave Wonderling (day 2)

In attendance:

NICE Staff:		
NICE attendee 1	Claire Ruiz	(day 1, day 2 morning only)

Observers:

NCGC Observer	Fiona Rooney	(day 2)
---------------	--------------	---------

Notes

1. The chair welcomed the group to the ninth and tenth GDG meeting (two day meeting). Apologies were received from Rachel O'Mahony. The Chair asked all GDG members to declare any relevant conflicts of interest. Henrietta Mulnier declared a personal non-pecuniary interest which was cleared in advance of the meeting. Henrietta has been invited to join a working group funded by Novo Nordisk to develop a new education and support programme. Payment has been declined and only reasonable travel and accommodation expenses will be accepted. The chair deemed that this is not a conflict of interest.

Notes

2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.
3. Linking evidence to recommendations for SMBG targets, timing and frequency had been drafted since the last meeting and was reviewed. Some changes were agreed.
4. Clinical and cost effectiveness evidence was reviewed for SMBG technology.
5. Evidence for diagnosis was revisited, with data extracted within one year of diagnosis. The linking evidence to recommendations table was updated.
6. An update was given on inputs for the core diabetes model.
7. Clinical and cost effectiveness evidence was discussed for inpatient ketone monitoring (ketone monitoring was previously discussed at GDG2). The linking evidence to recommendations table was updated.
8. Clinical effectiveness evidence for HbA1c targets and frequency was reviewed. The linking evidence to recommendations table was drafted.
9. There was no other business.

Date, time and venue of the next meeting

Tuesday 26th November 2013, from 1000 – 1600 at the National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ.